NCT03124121View on ClinicalTrials.gov

Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels

PHASE4CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

September 5, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Ulcerative Colitis
Interventions
DRUG

Golimumab

A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha

Trial Locations (1)

Unknown

Guy's & St Thomas' NHS Foundation Trust, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Guy's and St Thomas' NHS Foundation Trust

OTHER

NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels | Biotech Hunter | Biotech Hunter